Constant exchange rate (CER); in actual exchange rate (AER) +15.0%
Including active pharmaceutical ingredients (API), highly potent API (HPAPI), dosage form and delivery systems and particle engineering
Including mammalian, microbial, bioconjugates and cell and gene therapy products (personalized medicines are included for pre-clinical and clinical molecules only, early development services are included for pre-clinical molecules only)
Based on distinct companies
Would you like to view the 2022 Annual Report or the latest edition?